Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - Feb 15, 2022 - P1 | N=28 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | N=55 ➔ 28
Enrollment change • Melanoma • Oncology • Solid Tumor
|